Passage Bio (PASG)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	32.29 mm	32.29 mm	32.29 mm	32.29 mm	32.29 mm	32.29 mm
Cash burn (monthly)	(no burn)	107.25 k	6.90 mm	6.21 mm	2.48 mm	4.92 mm
Cash used (since last report)	n/a	544.99 k	35.07 mm	31.58 mm	12.61 mm	25.00 mm
Cash remaining	n/a	31.75 mm	-2.77 mm	712.48 k	19.68 mm	7.30 mm
Runway (months of cash)	n/a	296.0	-0.4	0.1	7.9	1.5

Beta Read what these cash burn values mean

Financial data from Passage Bio earnings reports.

Institutional ownership, Q3 2024

PASG institutional ownership history Ownership history

81.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	50	20	+150.0%
Opened positions	35	2	+1650.0%
Closed positions	5	36	-86.1%
Increased positions	3	2	+50.0%
Reduced positions	0	3	EXIT

13F shares	Current	Prev Q	Change
Total value	26.52 bn	5.01 bn	+429.1%
Total shares	50.01 mm	30.49 mm	+64.0%
Total puts	0.00	0.00
Total calls	7.70 k	0.00	NEW
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Orbimed Advisors	9.82 mm	$6.88 bn	+22.3%
Lynx1 Capital Management	8.43 mm	$5.90 bn	NEW
Vestal Point Capital	6.10 mm	$4.27 bn	NEW
Access Industries	2.62 mm	$16.62 mm	0.0%
Frazier Life Sciences IX	2.54 mm	$2.38 mm	0.0%
New Leaf Ventures III	2.50 mm	$63.87 mm	0.0%
New Leaf Venture Partners, L.L.C.	2.50 mm	$1.75 bn	NEW
Erste Asset Management GmbH	2.46 mm	$1.72 bn	NEW
LAV Prescience	2.20 mm	$13.97 mm	0.0%
Vanguard	2.07 mm	$1.45 bn	NEW

Largest transactions	Shares	Bought/sold	Change
Lynx1 Capital Management	8.43 mm	+8.43 mm	NEW
Vestal Point Capital	6.10 mm	+6.10 mm	NEW
Versant Venture Capital VI	0.00	-4.03 mm	EXIT
Versant Venture Management	0.00	-4.03 mm	EXIT
New Leaf Venture Partners, L.L.C.	2.50 mm	+2.50 mm	NEW
Erste Asset Management GmbH	2.46 mm	+2.46 mm	NEW
Vanguard	2.07 mm	+2.07 mm	NEW
Orbimed Advisors	9.82 mm	+1.79 mm	+22.3%
Tang Capital Management	1.50 mm	+1.50 mm	NEW
BlackRock	721.74 k	+721.74 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

PASG insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
11 Feb 25	Kathleen Borthwick	Common Stock	Sell	Dispose S	No	No	0	3,183	0.00	41,283
10 Feb 25	Kathleen Borthwick	Common Stock	Option exercise	Acquire M	No	No	0	8,000	0.00	44,466
10 Feb 25	Kathleen Borthwick	RSU Common Stock	Option exercise	Dispose M	No	No	0	8,000	0.00	0
14 Jan 25	Orbimed Advisors	Common Stock	Sell	Dispose S	Yes	No	0.6	79,024	47.41 k	7,034,626
13 Jan 25	Orbimed Advisors	Common Stock	Sell	Dispose S	Yes	No	0.64	17,986	11.51 k	7,113,650
10 Jan 25	Orbimed Advisors	Common Stock	Sell	Dispose S	Yes	No	0.66	126,209	83.30 k	7,131,636
8 Jan 25	Orbimed Advisors	Common Stock	Sell	Dispose S	Yes	No	0.68	75,007	51.00 k	7,257,845
7 Jan 25	Orbimed Advisors	Common Stock	Sell	Dispose S	Yes	No	0.71	52,536	37.30 k	7,332,852
6 Jan 25	Orbimed Advisors	Common Stock	Sell	Dispose S	Yes	No	0.77	19,481	15.00 k	7,385,388
27 Dec 24	Lynx1 Capital Management	Common stock, $0.0001 par value per share	Buy	Acquire P	Yes	No	0.6451	373,645	241.04 k	9,256,953

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Passage Bio Reported Updated Data From The Ongoing Phase 1/2 upliFT-D Trial Of PBFT02 For Frontotemporal Dementia With Granulin Mutations

10 Jan 25

Updated interim data from FTD-GRN patients treated with Dose 1 PBFT02:BiomarkersDose 1 of PBFT02 treatment resulted in a robust and durable increase in PGRN expression.PBFT02 consistently increased CSF PGRN expression in

12 Health Care Stocks Moving In Thursday's Pre-Market Session

2 Jan 25

Press releases

From Benzinga Pro

Passage Bio to Participate in Upcoming Investor Conferences

26 Feb 25

PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced

Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates

10 Jan 25

PBFT02 demonstrated durable, elevated CSF PGRN levels and early evidence of reduction in plasma NfL levels, a disease progression biomarker, compared to published natural history data Evaluating Dose 2, 50% lower than